Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Global Bio-chem Technology Group Co. Ltd. ( (HK:0809) ) is now available.
Global Bio-chem Technology Group’s indirect wholly owned subsidiary Changchun Dacheng Dahe Bio-tech Development has signed a cooperation agreement with Shenzhou Bio-tech for the production of coenzyme Q10 mycelium in China. Under the deal, Shenzhou Bio-tech will provide proprietary strains, technology and process parameters, while Dacheng Dahe will upgrade its facilities to meet agreed output levels and supply a minimum of 1,270 metric tonnes of coenzyme Q10 between January 2027 and December 2028.
The partnership links Global Bio-chem with a Shenzhou Bio-tech shareholder backed by state-owned China Resources Pharmaceutical Group, giving the group access to new markets and technical know-how in biological fermentation. Management expects the agreement to enhance production efficiency, accelerate business development and raise brand visibility in the mainland Chinese market, aligning with its long-term strategic objectives and potentially strengthening its competitive position in the sector.
More about Global Bio-chem Technology Group Co. Ltd.
Global Bio-chem Technology Group Company Limited is a bio-technology group incorporated in the Cayman Islands and listed in Hong Kong, operating through subsidiaries in the People’s Republic of China. The group focuses on bio-based products and fermentation technologies, positioning itself within the broader biochemical and bio-fermentation industry with an emphasis on industrial-scale production.
Average Trading Volume: 5,257,607
Technical Sentiment Signal: Sell
Current Market Cap: HK$956.9M
Learn more about 0809 stock on TipRanks’ Stock Analysis page.